Methods | RCT | |
Participants |
Setting: Hospital Maternidad Concepcion Palacios, Caracas, Venezuela. Inclusion criteria: women of legal age (aged ≥ 18 years), who were able to communicate meaningfully with the nurse‐observer, who were hospitalised and had severe post episiotomy pain after an uncomplicated birth and could tolerate oral medications Exclusion criteria: planning to breast feed within 24 hours after administration of the study medications; serious complicating illness or abnormal postpartum bleeding, with active peptic ulcer disease or other gastrointestinal disease associated with blood loss; receipt of any other investigational drug within the 1 month prior; history of drug or alcohol abuse; known allergic sensitivities to aspirin, diclofenac, or other NSAIDs |
|
Interventions |
Aspirin (N = 50 randomised) 650 mg aspirin; single oral dose of 2 x 325 mg capsules; and 3 placebo tablets Placebo (N = 52 randomised) Placebo; single oral dose of 2 placebo capsule and 3 placebo tablets All women: each woman received a single unit dose consisting 2 capsules and 3 tablets, with at least 8 ounces of water; women were asked to sit up or lie on their right side for 2 hours after administration. No medications (analgesics, sedatives, hypnotics, tranquillisers) were permitted concomitantly or during the 4 hours prior to taking the medication |
|
Outcomes |
Adequate pain relief as reported by the woman: the same nurse‐observer interviewed the women at 0.5 hours, and hourly for 8 hours
Need for additional pain relief in the first 48 hours for perineal pain: re‐medication within 8‐hour study period Maternal adverse effects: adverse effects were recorded if they were observed or volunteered |
|
Notes |
Funding: "This work was supported in part by a grant from the Ciba‐Geigy Corporation, Summit, NJ" Declarations of interests: not reported; though first and second authors affiliated to "Analgesic Development Ltd." Additional arms: this was a 5‐arm trial also assessed diclofenac potassium 25 mg (N = 52), 50 mg (N = 50) and 100 mg (N = 51); we have only included the relevant arms in this review |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Quote: "randomly assigned… computer program generated a random permutation such that two patients received each treatment" |
Allocation concealment (selection bias) | Unclear risk | No detail provided |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | Quotes: "double‐blind" and "Each patient received a single‐unit dose consisting of 3 tablets and 2 capsules… all unit doses were identical in appearance and packaging" |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | 1 nurse observer involved in outcome assessment |
Incomplete outcome data (attrition bias) All outcomes | High risk | If a woman wished to withdraw before the first hour because of inadequate relief, a non‐study analgesic was administered, and she was discontinued from the study (none were re‐medicated in this first hour; therefore no discontinuations); if a woman required additional analgesic after the first hour, she was included, and relief scores of 0 and intensity scores equal to the pain at time of re‐medication were assumed for the duration (5/50 in the aspirin group 19/52 in the placebo group) |
Selective reporting (reporting bias) | Unclear risk | No access to trial protocol to further assess risk of selective reporting |
Other bias | Low risk | Baseline characteristics reported (age, weight, height, parity, days post‐delivery) were comparable between groups; no other obvious sources of bias identified |